- Home
- AOD vs URGN Comparison
AOD vs URGN Comparison
Compare AOD & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOD
- URGN
- Stock Information
- Founded
- AOD 2006
- URGN 2004
- Country
- AOD United Kingdom
- URGN United States
- Employees
- AOD N/A
- URGN N/A
- Industry
- AOD Investment Managers
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- AOD Finance
- URGN Health Care
- Exchange
- AOD Nasdaq
- URGN Nasdaq
- Market Cap
- AOD 959.4M
- URGN 904.0M
- IPO Year
- AOD N/A
- URGN 2017
- Fundamental
- Price
- AOD $9.10
- URGN $19.34
- Analyst Decision
- AOD
- URGN Strong Buy
- Analyst Count
- AOD 0
- URGN 8
- Target Price
- AOD N/A
- URGN $28.50
- AVG Volume (30 Days)
- AOD 423.5K
- URGN 1.1M
- Earning Date
- AOD 01-01-0001
- URGN 08-07-2025
- Dividend Yield
- AOD 12.95%
- URGN N/A
- EPS Growth
- AOD 213.63
- URGN N/A
- EPS
- AOD 1.93
- URGN N/A
- Revenue
- AOD $72,962,082.00
- URGN $94,238,000.00
- Revenue This Year
- AOD N/A
- URGN $35.60
- Revenue Next Year
- AOD N/A
- URGN $129.54
- P/E Ratio
- AOD $4.44
- URGN N/A
- Revenue Growth
- AOD N/A
- URGN 10.85
- 52 Week Low
- AOD $6.99
- URGN $3.42
- 52 Week High
- AOD $9.14
- URGN $21.02
- Technical
- Relative Strength Index (RSI)
- AOD 59.31
- URGN 55.13
- Support Level
- AOD $9.00
- URGN $18.41
- Resistance Level
- AOD $9.17
- URGN $19.80
- Average True Range (ATR)
- AOD 0.06
- URGN 0.86
- MACD
- AOD -0.00
- URGN -0.24
- Stochastic Oscillator
- AOD 68.42
- URGN 48.45
About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest
Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.